Synthetic heptapeptide
Semax
ACTH(4-7)-Pro-Gly-Pro
Not FDA-approved in the U.S.A synthetic peptide studied for neurobiological effects, with a body of mostly small, regional, or preclinical research.
FULL RESEARCH GRAPHIC
Semax research overview
A dedicated overview of Semax, cognition and stress-response research, and the 10 mg vial.
Tap the graphic to open the full-resolution version.
RESEARCH SIGNAL MAP
04 ACTIVE FIELDSEVIDENCE READOUT
Not FDA-approved in the U.S.Small studies and mechanistic findings do not establish general cognitive enhancement, long-term safety, or equivalence across formulations.
BOUNDARY CHECK
CONTEXT REQUIREDFDA states that safety information for proposed compounded routes is absent or limited and that immunogenicity and impurity risks may be present.
SUBMITTED LAB DOCUMENTS
Test results
Reports may describe other strengths or blends. Match the labeled amount, composition, and exact lot to your vial. A report for another strength does not verify your vial. Each record identifies whether an exact lot was supplied.
VIAL REFERENCE
3 mL mixing math & dosing context
Every number is labeled by evidence level. The 3 mL reference calculates concentration and U-100 volume; it does not prove solvent compatibility, sterility, stability, or suitability for injection.
10 mg vial
Change the liquid. See the amount.
Calculation only: vial amount ÷ liquid volume × draw volume. It does not determine what dose to use or confirm product compatibility.
3.0 mL BAC-water workflow
- First confirm that bacteriostatic water and a 3.0 mL final volume are compatible with the exact product and vial capacity.
- Clean both vial stoppers with alcohol and allow them to dry.
- Add the 3.0 mL slowly down the inside wall instead of directing pressure onto the powder.
- Gently roll or swirl until dissolved; do not shake.
- Use product-specific refrigeration and discard guidance. If none exists, do not invent a beyond-use date.
No standardized U.S. human dose
Semax is not FDA-approved in the United States. Available evidence does not establish one validated dose across intranasal and subcutaneous routes or across differently formulated products.
FDA — compounding safety risks ↗U-100 means 100 units = 1.0 mL. Any table result above 100 units exceeds one standard 1 mL U-100 syringe.